Boston Scientific CorporationBSXNYSE
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank57
3Y CAGR-19.8%
Year-over-Year Change
Price-to-earnings ratio
3Y CAGR
-19.8%/yr
vs +34.2%/yr prior
Acceleration
-54.0pp
Decelerating
Percentile
P57
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 48.91 | -31.0% |
| 2024 | 70.89 | +34.4% |
| 2023 | 52.73 | -44.4% |
| 2022 | 94.83 | +63.2% |
| 2021 | 58.10 | +109.4% |
| 2020 | -621.10 | -4739.2% |
| 2019 | 13.39 | -54.2% |
| 2018 | 29.21 | -91.1% |
| 2017 | 326.58 | +285.9% |
| 2016 | 84.63 | - |